The Glycaemic Load: Why Insulin Sensitivity is the Primary Marker of Longevity

Overview

To accurately evaluate human biological decay and metabolic longevity, one must first deconstruct the paradigm of carbohydrate metabolism beyond the simplistic, reductionist lens of the glycaemic index. As extensively documented in longitudinal epidemiological cohorts and metabolic ward trials published in The Lancet and Cell Metabolism, the ingestion of high glycaemic load (GL) diets chronically overburdens the endocrine pancreas. This persistent hyperinsulinaemia acts as a master switch, fundamentally altering systemic physiology. When glucose absorption outpaces cellular oxidative capacity, postprandial hyperglycaemia triggers a compensatory surge of insulin secretion from pancreatic beta cells. Over time, this state of chronic hyperinsulinaemia downregulates peripheral insulin receptors, primarily on skeletal muscle and hepatic tissue, driving the insidious progression toward systemic insulin resistance—the primary bottleneck of human healthspan.

At INNERSTANDIN, our analysis of metabolic flux reveals that insulin is not merely a regulator of blood glucose homeostasis; it is an evolutionarily conserved master anabolic peptide and a potent driver of molecular ageing. Chronically elevated insulin concentrations systematically suppress macro-autophagy via the hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1), while simultaneously inhibiting AMP-activated protein kinase (AMPK). This biochemical blockade prevents the clearance of dysfunctional mitochondria and misfolded proteins, accelerating cellular senescence across vascular endothelium, neural networks, and visceral adipose depots. Furthermore, persistent insulin resistance compromises phosphatidylinositol 3-kinase (PI3K) signalling pathways, impairing endothelial nitric oxide synthase (eNOS) activation. The resulting endothelial dysfunction underpins the pathogenesis of atherosclerosis, hypertension, and microvascular disease, which remain leading causes of morbidity within the UK population as tracked by Office for National Statistics health metrics.

Examining the mechanistic underpinnings further, high glycaemic load meals provoke excessive advanced glycation end-products (AGEs) formation via non-enzymatic glycation cascades. These circulating AGEs bind to their cellular receptors (RAGE), propagating nuclear factor kappa B (NF-$\kappa$B) transcription and chronic, low-grade systemic inflammation—often termed "inflammageing." This persistent inflammatory milieu exacerbates tissue-specific insulin resistance, establishing a self-perpetuating pathological loop. Therefore, preserving or restoring insulin sensitivity is not merely a strategy for glycaemic control or metabolic syndrome mitigation; it is the fundamental biomarker and mechanistic driver of biological longevity. By mitigating postprandial glucose excursions and lowering the overall glycaemic load, one preserves beta-cell reserve, reactivates cellular clearance mechanisms, and dampens systemic inflammatory cascades, thereby extending the healthspan by targeting the root endocrinological pathways of cellular senescence.

The Biology — How It Works

At the cellular level, chronic hyperinsulinaemia acts as a master-regulator of metabolic senescence, dismantling longevity pathways through well-documented enzymatic and transcriptional cascades. When dietary glycaemic load (GL) consistently exceeds the oxidation and storage capacity of skeletal muscle, postprandial glucose excursions force pancreatic beta-cells to upregulate insulin secretion. This sustained elevation of circulating insulin alters the stoichiometric ratio between insulin and glucagon, persistently activating the mammalian target of rapamycin complex 1 (mTORC1) while concurrently suppressing AMP-activated protein kinase (AMPK)—the evolutionary gatekeeper of cellular energy homeostasis and autophagy. As demonstrated in landmark molecular gerontology studies published in The Lancet and Cell Metabolism, chronic suppression of AMPK inhibits unc-51-like autophagy-activating kinase 1 (ULK1) phosphorylation, effectively halting macroautophagy and precipitating the intracellular accumulation of damaged mitochondria, misfolded proteins, and advanced glycation end-products (AGEs).

Concurrently, hyperinsulinaemia downregulates the expression of the nuclear receptor peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1$\alpha$), the master transcriptional coactivator of mitochondrial biogenesis. In insulin-resistant states, unchecked serine phosphorylation of insulin receptor substrate 1 (IRS-1) by serine/threonine kinases—such as c-Jun N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B kinase subunit beta (IKK$\beta$)—disrupts canonical phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signalling. This molecular blockade prevents the translocation of glucose transporter type 4 (GLUT4) vesicles to the sarcolemma in myocytes and the adipocyte plasma membrane, exacerbating systemic glucose intolerance. Furthermore, chronic insulin resistance hyperactivates the transcription factor sterol regulatory element-binding protein 1c (SREBP-1c) within hepatocytes, driving de novo lipogenesis and promoting non-alcoholic fatty liver disease (NAFLD), a prevalent comorbidity across the UK population that independently accelerates cardiovascular morbidity.

At the endothelial interface, the loss of metabolic insulin signalling uncouples the endothelial nitric oxide synthase (eNOS) pathway while preserving the endothelin-1 (ET-1)-mediated vasoconstrictive axis. Insulin physiologically stimulates eNOS via the Akt pathway to produce nitric oxide (NO), maintaining vascular tone and endothelial integrity. When insulin resistance sets in, this pathway is selectively blunted, whereas mitogen-activated protein kinase (MAPK) signalling remains intact, driving unchecked endothelin-1 expression, vascular smooth muscle cell proliferation, and low-grade chronic inflammation characterised by elevated circulating IL-6 and high-sensitivity C-reactive protein (hs-CRP).

These interconnected mechanisms clarify why biological platforms like INNERSTANDIN emphasise glycaemic load modulation not merely for glycaemic control, but as a foundational prerequisite for preserving proteostasis, mitochondrial function, and vascular compliance across the human lifespan. Mitigating postprandial glucose spikes reduces the chronic evolutionary mismatch between modern carbohydrate-dense diets and our conserved metabolic machinery, resetting insulin sensitivity to delay the systemic hallmarks of biological ageing.

Mechanisms at the Cellular Level

At the subcellular level, chronic elevation of the glycaemic load orchestrates a pathological cascade that fundamentally compromises cellular homeostasis and accelerates biological ageing. When postprandial glucose excursions persistently challenge physiological limits, pancreatic beta-cells respond with compensatory hyperinsulinaemia. This hyperinsulinaemic state forces sustained engagement of the insulin receptor (IR) and its downstream effectors, primarily the insulin receptor substrates (IRS-1 and IRS-2). Chronic phosphorylation of these substrates on inhibitory serine residues—rather than the physiological activating tyrosine residues—induces profound peripheral insulin resistance. As documented in landmark molecular physiology literature published in The Lancet and Cell Metabolism, this disruption blunts the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signalling axis. The consequence is a catastrophic failure in glucose transporter type 4 (GLUT4) translocation to the plasma membrane, locking the cell in a state of glucotoxicity despite an abundance of circulating fuel.

With the PI3K-AKT pathway chronically uncoupled from metabolic regulation, downstream mammalian target of rapamycin (mTOR) complex 1 experiences aberrant, tonic hyperactivation. This suppresses macroautophagy—the vital cellular recycling programme required for the clearance of damaged organelles and misfolded proteins. Concurrently, mitochondrial overload ensues. The relentless influx of glucose exceeds the oxidative capacity of the tricarboxylic acid (TCA) cycle, driving electrons into the mitochondrial electron transport chain at an unsustainable rate. This results in premature leakage at complexes I and III, culminating in an overproduction of reactive oxygen species (ROS). These intracellular oxidants directly damage mitochondrial DNA, oxidize membrane lipids, and trigger the opening of the mitochondrial permeability transition pore, initiating apoptosis.

Furthermore, this intracellular oxidative milieu acts as a potent second messenger system activating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-$\kappa$B). Translocation of NF-$\kappa$B to the nucleus upregulates the transcription of pro-inflammatory cytokines, including tumour necrosis factor-alpha (TNF-$\alpha$) and interleukin-6 (IL-6), which feed back to exacerbate serine kinase activation (such as JNK and IKK$\beta$) and deepen cellular insulin resistance. This self-propagating inflammatory loop is compounded by the non-enzymatic glycation of intracellular proteins and nucleic acids, driven by elevated intracellular glucose and its reactive dicarbonyl byproducts like methylglyoxal. These advanced glycation end-products (AGEs) bind to their cell-surface receptor (RAGE), further amplifying oxidative stress and fibrotic signalling pathways.

For the discerning readership of INNERSTANDIN, the physiological reality is unequivocal: the glycaemic load is not merely a metric of carbohydrate digestion; it is the primary biochemical driver of intracellular decay. By uncoupling nutrient-sensing pathways, overwhelming mitochondrial integrity, and locking the cell in a perpetual loop of sterile inflammation and lipotoxicity, chronic high glycaemic loads dismantle the cellular machinery of longevity at its very roots. Preserving insulin sensitivity is therefore not just a matter of metabolic management, but the fundamental prerequisite for maintaining genomic stability and cellular integrity across the human lifespan.

Environmental Threats and Biological Disruptors

Modern anthropogenic environments present a multi-faceted matrix of metabolic stressors that systematically erode human insulin sensitivity, shifting the physiological baseline from metabolic homeostasis toward chronic low-grade inflammation and accelerated senescence. Epidemiological data monitored by UK public health bodies underscore an inverse correlation between industrialisation, urban particulate exposure, and glycaemic control. At the molecular level, environmental disruptors operate via distinct pathways, exacerbating the postprandial glycemic load and crippling the pancreatic beta-cell's compensatory mechanisms.

Foremost among these disruptors are persistent organic pollutants (POPs) and endocrine-disrupting chemicals (EDCs), including bisphenols, phthalates, and polychlorinated biphenyls (PCBs), which are lipophilic xenobiotics abundantly present in modern food chains and packaging. As demonstrated in toxicological assays published in The Lancet Diabetes & Endocrinology, these compounds function as obesogens and metabolic disruptors by acting as agonists for nuclear receptors, most notably the peroxisome proliferator-activated receptor gamma (PPAR-$\gamma$) and the pregnane X receptor (PXR). When xenobiotics bind to these transcriptional regulators, they dysregulate adipocyte differentiation, promote ectopic lipid deposition within skeletal muscle and hepatic parenchyma, and induce insulin resistance via the upregulation of serine phosphorylation cascades on insulin receptor substrate-1 (IRS-1). This targeted inhibition blocks downstream phosphatidylinositol 3-kinase (PI3K)/Akt signalling, directly impairing translocation of glucose transporter type 4 (GLUT4) to the plasma membrane.

Simultaneously, inhalable fine particulate matter ($\text{PM}_{2.5}$), a pervasive urban pollutant documented extensively in British epidemiological cohorts, triggers a systemic inflammatory cascade that profoundly impacts metabolic health. Inhaled nanoparticles cross the alveolar-capillary membrane, translocating into the systemic circulation and activating pulmonary macrophages. This initiates the continuous release of pro-inflammatory cytokines—specifically tumour necrosis factor-alpha (TNF-$\alpha$), interleukin-6 (IL-6), and C-reactive protein (CRP)—into the bloodstream. At the cellular level, TNF-$\alpha$ activates c-Jun N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B kinase subunit beta (IKK$\beta$). These serine kinases phosphorylate IRS-1 on inhibitory serine residues (such as Ser307), uncoupling the insulin receptor from its intracellular signalling network. Consequently, even in the absence of an acute dietary glycaemic challenge, systemic pollutant-induced inflammation chronically suppresses tissue-level glucose disposal.

Furthermore, chronobiological disruption driven by artificial light at night (ALAN) and shift work overrides the central pacemaker in the suprachiasmatic nucleus (SCN), desynchronising peripheral molecular clocks residing within metabolic organs like the liver, skeletal muscle, and endocrine pancreas. Circadian clock proteins—such as CLOCK and BMAL1—directly regulate the transcription of genes governing hepatic gluconeogenesis, insulin synthesis, and glucose utilisation. Chronic circadian misalignment dampens the rhythmic expression of these core clock genes, resulting in impaired diurnal glucose tolerance, elevated nocturnal free fatty acid flux, and accelerated hepatic glycogenolysis.

At INNERSTANDIN, we emphasize that these environmental stressors do not merely act as isolated irritants; they converge synergistically with high-glycaemic dietary loads. By compounding cellular insulin resistance, ambient toxins and circadian disruption ensure that every carbohydrate-dense meal produces an exaggerated, prolonged hyperinsulinaemic response. This relentless metabolic friction exhausts pancreatic reserve, drives mitochondrial dysfunction, and ultimately accelerates cellular senescence, confirming that preservation of insulin sensitivity is fundamentally contingent upon mitigating these pervasive environmental insults.

The Cascade: From Exposure to Disease

Chronically elevated glycaemic loads initiate a pernicious biochemical cascade that fundamentally alters systemic physiology, progressively eroding cellular integrity and precipitating age-related pathology. When an individual consumes high-load carbohydrates, postprandial blood glucose surges violently, necessitating a compensatory, hyper-physiologic release of insulin from the pancreatic $\beta$-cells. As established in seminal epidemiological and mechanistic studies published in The Lancet and Diabetes Care, this repeated demand for supraphysiological hyperinsulinaemia acts as the primary systemic driver of receptor downregulation. Target tissues—predominantly skeletal muscle, hepatic parenchyma, and adipose depots—downregulate their cell-surface GLUT4 glucose transporters to protect themselves from intracellular glucotoxicity. This acquired receptor desensitisation is the hallmark of insulin resistance, setting the stage for a systemic metabolic blockade.

At the molecular level, persistent hyperinsulinaemia and hyperglycaemia synergistically activate intracellular stress pathways, most notably protein kinase C (PKC) isoforms, nuclear factor kappa B (NF-$\kappa$B), and mammalian target of rapamycin (mTOR) hyperactivation. According to findings archived in PubMed-indexed molecular pathology literature, this metabolic milieu exponentially increases the production of reactive oxygen species (ROS) within the mitochondrial electron transport chain. The resulting oxidative stress damages mitochondrial DNA and structural lipids, driving premature cellular senescence. Concurrently, excess intracellular glucose undergoes non-enzymatic glycation with circulating proteins and lipids, culminating in the irreversible formation of advanced glycation end-products (AGEs). These AGEs bind to their endogenous receptors (RAGE), triggering a sustained, low-grade inflammatory state characterised by the chronic upregulation of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-$\alpha$), and C-reactive protein (CRP).

This inflammatory and glycotoxic cascade does not remain localised; its systemic sequelae manifest across every major organ system, mirroring the accelerated phenotypic ageing documented by large-scale UK biobank cohorts. In the vasculature, chronic hyperinsulinaemia and AGE accumulation impair endothelial nitric oxide synthase (eNOS) activity, robbing arteries of vasoprotective nitric oxide and inducing endothelial dysfunction—the foundational step in atherosclerosis. Simultaneously, hepatic lipid de novo lipogenesis is persistently driven by elevated insulin and carbohydrate-responsive element-binding protein (ChREBP) signalling, precipitating non-alcoholic fatty liver disease (NAFLD) and atherogenic dyslipidaemia (hypertriglyceridaemia coupled with small, dense LDL particles). In the central nervous system, impaired insulin signalling disrupts neuronal glucose uptake and brain-derived neurotrophic factor (BDNF) expression, accelerating cerebral atrophy and cognitive decline. At INNERSTANDIN, our synthesis of this pathophysiological trajectory is unequivocal: viewing chronic disease as a collection of isolated pathologies is a critical diagnostic failure. By failing to control the glycaemic load, the organism is subjected to an unyielding biochemical assault that systematically compromises insulin sensitivity, turning the body's primary storage hormone into an agent of systemic destruction and premature senescence.

What the Mainstream Narrative Omits

To comprehend metabolic longevity fully, one must first deconstruct the reductionist paradigm promoted by contemporary public health frameworks. Mainstream dietary guidelines continue to evaluate carbohydrates primarily through the prism of the glycaemic index (GI)—a measure tracking the velocity of postprandial glucose elevation. However, as established in seminal pharmacokinetic evaluations indexed in PubMed, the GI metric suffers from a critical structural flaw: it measures carbohydrate quality at a standardized mass of 50 grams, completely ignoring the real-world density of ingested macronutrients. This is where the glycaemic load (GL) emerges as the superior physiological metric, multiplying the glycaemic index by the total available carbohydrate content per serving. Yet, even the GL metric remains incomplete without evaluating the hyperinsulinaemic counter-regulatory response required to achieve glucose homeostasis.

What the mainstream narrative persistently omits is that normoglycaemia does not equate to metabolic health. Clinical data published in journals such as The Lancet demonstrates that individuals can maintain normal fasting blood glucose and HbA1c levels for decades while simultaneously hyper-secreting insulin from pancreatic beta cells to overcome escalating peripheral insulin resistance. This compensatory hyperinsulinaemia is the hidden driver of biological senescence. Chronic elevation of circulating insulin suppresses macroautophagy and downregulates AMP-activated protein kinase (AMPK), shifting cellular machinery away from vital housekeeping, DNA repair, and mitochondrial biogenesis, and locking the organism into an anabolic, pro-inflammatory state governed by mechanistic target of rapamycin (mTOR) overactivation.

Within the context of the United Kingdom—where National Health Service data highlights an escalating burden of metabolic syndrome and Type 2 diabetes—public health messaging remains tethered to calorie counting and broad-brush stroke reductionist advice. It fails to educate the populace on the insidious nature of high-GL dietary patterns on endothelial dysfunction and advanced glycation end-product (AGE) accumulation. Insulin is not merely a storage hormone for glucose; it is a master regulator of vascular tone, sympathetic nervous system activity, and renal sodium reabsorption. When chronic high-GL loads force sustained hyperinsulinaemia, the endothelium undergoes phenotypic switching, characterized by reduced endothelial nitric oxide synthase (eNOS) activation and heightened expression of vascular cell adhesion molecules (VCAM-1).

Furthermore, mainstream nutritional epidemiology frequently relies on food-frequency questionnaires that obscure the distinct mechanistic pathways of hyper-processed, high-GL matrices versus whole-food matrices containing unrefined cellular structures. At INNERSTANDIN, our synthesis of current molecular physiology dictates a paradigm shift: longevity cannot be decoupled from the preservation of receptor-level insulin sensitivity. Mitigating the cumulative glycaemic load is not merely a strategy for glycaemic control; it is the primary physiological intervention required to preserve metabolic flexibility, attenuate chronic sterile inflammation, and extend human healthspan.

The UK Context

To fully comprehend the imperative nature of metabolic optimisation, one must examine the epidemiological landscape of the British Isles through a pathophysiological lens. Within the United Kingdom, the standard institutional paradigm has historically prioritized reactive pharmacotherapy over preventative metabolic modulation, a systemic failing laid bare by successive health surveys. Data extrapolated from the Health Survey for England and longitudinal cohorts published in The Lancet Diabetes & Endocrinology consistently demonstrate a burgeoning prevalence of hyperinsulinaemia, pre-diabetes, and type 2 diabetes that directly correlates with the industrialised ubiquity of high-glycaemic-load dietary staples. When populations chronically ingest refined carbohydrates that bypass rapid gastric emptying controls and trigger precipitous spikes in postprandial blood glucose, the pancreatic beta-cells respond with compensatory hypersecretion of insulin. Over decades, this relentless demand accelerates beta-cell exhaustion and downregulates peripheral insulin receptors located on skeletal muscle and hepatic tissue.

At theINNERSTANDIN research laboratories, our analysis of UK-specific biobank metrics reveals that this chronic hyperinsulinaemia operates as an independent driver of systemic immunosenescence and vascular endothelial dysfunction. Elevated circulating insulin chronically suppresses macroautophagy—the cellular recycling mechanism critical for clearing misfolded proteins and senescent mitochondria—thereby accelerating cellular ageing across neurovascular and myocardial tissues. Furthermore, the British diet, heavily laden with ultra-processed foods possessing an aggressively high glycaemic index, fosters a pro-inflammatory internal milieu characterised by elevated C-reactive protein (CRP) and systemic upregulation of nuclear factor kappa B (NF-$\kappa$B). By failing to address the glycaemic load at a population level, clinical frameworks in the UK overlook the primary marker of biological aging. Restoring metabolic homeostasis requires a paradigmatic shift toward preserving insulin sensitivity, mitigating chronic postprandial glycaemic excursions, and fundamentally redefining nutritional policy away from outdated caloric models toward a precision-based physiological framework.

Protective Measures and Recovery Protocols

Mitigating the compounding pathophysiological cascades of hyperinsulinaemia requires targeted, mechanism-led interventions that restore cellular nutrient-partitioning efficiency. In alignment with recent clinical trials and population-wide health data compiled across the UK, shifting the focus from mere glycaemic avoidance to active receptor upregulation is paramount. To reverse peripheral and hepatic insulin resistance, clinical protocols must exploit the dual-action pathways of non-insulin-dependent glucose uptake and the attenuation of chronic, low-grade metabolic inflammation.

At the cellular level, the primary therapeutic target is the translocation of glucose transporter type 4 (GLUT4) vesicles to the plasma membrane. While insulin initiates this cascade via the canonical IRS-1/PI3K/Akt pathway, skeletal muscle contraction bypasses this route entirely through the activation of 5'-adenosine monophosphate-activated protein kinase (AMPK). Interventions that systematically deplete intracellular ATP pools—specifically high-intensity resistance training and structured zone-2 aerobic work—upregulate AMPK independently of insulin availability. As demonstrated in longitudinal studies published in The Lancet, this dual-activation model significantly enhances whole-body insulin sensitivity, effectively lowering baseline fasting insulin and reducing the glycaemic load penalty of subsequent dietary carbohydrate ingestion.

Nutritional biochemistry further dictates that recovery protocols must modulate the intestinal absorption kinetics of monosaccharides and suppress hepatic gluconeogenesis. The integration of viscous soluble fibres, such as beta-glucans and psyllium husk, forms a macroscopic gel matrix within the gastrointestinal lumen, physically delaying enzymatic carbohydrate hydrolysis and blunting the postprandial insulin spike. Concurrently, bioactive compounds including polyphenols (such as epigallocatechin gallate and berberine) function as potent natural inhibitors of protein tyrosine phosphatase 1B (PTP1B)—a known negative regulator of insulin receptor signalling. By inhibiting PTP1B, these agents prolong the phosphorylation state of the insulin receptor beta-subunit, restoring downstream metabolic signalling fidelity in previously desensitised hepatocytes and myocytes.

Furthermore, mitigating the systemic oxidative stress associated with chronic glycaemic variability is crucial for preserving pancreatic beta-cell functional mass. Reactive oxygen species (ROS) generated via mitochondrial overload during sustained hyperglycemia directly impair insulin gene expression and induce endoplasmic reticulum (ER) stress within the islets of Langerhans. Introducing exogenous antioxidants and optimising endogenous glutathione synthesis via targeted amino acid precursors—such as N-acetylcysteine—neutralises these radical species, preventing the apoptotic pathways that lead to irreversible beta-cell failure.

At INNERSTANDIN, we emphasize that true metabolic longevity is not achieved through passive dietary restriction, but through the deliberate, biochemically literate orchestration of protocols that enhance receptor affinity, clear intracellular lipid intermediates (diacylglycerols and ceramides) from skeletal muscle, and re-establish homeostatic insulin economy across all physiological systems.

Summary: Key Takeaways

Decades of epidemiological data—corroborated by landmark trials catalogued in The Lancet and indexed on PubMed—compel a radical realignment of how metabolic health is interrogated. The glycaemic load (GL) is not merely a dietary metric for glycaemic control; it is the primary deterministic variable governing chronic hyperinsulinaemia, mitochondrial degradation, and accelerated cellular senescence. As demonstrated in metabolic flux analyses, repeated high-GL dietary insults persistently over-stimulate pancreatic $\beta$-cells, downregulating peripheral insulin receptor density and entrenching systemic insulin resistance. This blunts PI3K-Akt signalling pathways, paradoxically upregulating hepatic de novo lipogenesis while starving myocytes of necessary glucose equivalents. Furthermore, chronic insulin resistance chronically suppresses autophagy via hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1), accelerating vascular endothelial dysfunction, advanced glycation end-product (AGE) accumulation, and systemic low-grade inflammation—the hallmark phenotypes of biological aging. Consequently, preserving insulin sensitivity through the systematic minimisation of glycaemic load emerges as the paramount biochemical intervention for extending human healthspan. At INNERSTANDIN, we assert that shifting the clinical paradigm from glucose management to insulin sensitivity optimisation is the single most efficacious strategy for mitigating metabolic morbidity.